Bilateral AMD and comorbidities can negatively affect injection adherence, while clinician consistency and caregiver education can encourage it.

D-150 demonstrated consistent and durable benefit across all three patient cohorts as evidenced by maintenance of visual acuity, control of ...

Trial Superiority Testing -- Statistical analysis plan allows for hierarchical testing of superiority after non-inferiority ...

Bispecific antibody treatments remain a promising treatment for diabetic macular edema (DME), as a new study shows that faricimab was effective and had durable results after a year of real-world ...

A 70-year-old man presented to Tufts emergency department with a 2-day history of left eye redness and periorbital swelling ...

Ocular Therapeutix Inc (OCUL) showcases robust trial progress and financial positioning, while navigating regulatory and ...

“In people who have diabetes, when they’re on GLP-1s, they experience an early increase in the risk of diabetic retinopathy,” ...

Cash balance of $344.8 million as of September 30, 2025, together with net proceeds of ~$445 million from October 2025 equity offering, with expected runway into 2028 BEDFORD, Mass., Nov. 04, 2025 ...

Research and development expenses for the third quarter of 2025 were $52.4 million versus $37.1 million for the comparable quarter in 2024, reflecting an increase in overall clinical expenses ...

D Molecular Therapeutics (4DMT) has announced an exclusive licence agreement with Otsuka Pharmaceutical to develop and market ...

Otsuka Pharma enters licensing agreement with 4D Molecular Therapeutics for ophthalmic gene therapy drug candidate, 4D-150: Tokyo Monday, November 3, 2025, 11:00 Hrs [IST] Otsuka ...

Otsuka Pharmaceuticals could shell out over $400 million in total for the Asia-Pacific rights to 4D-150, which combines a ...